Ismini Vassilaki
Overview
Explore the profile of Ismini Vassilaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vikstrom S, Mikiver R, Lapins J, Nielsen K, Vassilaki I, Lyth J, et al.
Br J Dermatol
. 2023 Jul;
189(6):702-709.
PMID: 37463416
Background: Melanoma-specific survival (MSS) is heterogenous between stages and is highly dependent on the T stage for primary localized disease. New systemic therapies for metastatic cutaneous melanoma (CM) have been...
2.
Helgadottir H, Schultz K, Lapins J, Vassilaki I, All-Eriksson C, Hoiom V
Acta Oncol
. 2023 Jun;
62(6):565-570.
PMID: 37265265
No abstract available.
3.
Aristokleous I, Schultz I, Vassilaki I, Krynitz B, Lapins J, Girnita A, et al.
J Plast Reconstr Aesthet Surg
. 2022 Jun;
75(9):3373-3383.
PMID: 35643596
Mohs micrographic surgery is the preferred surgical option for high-risk basal cell carcinomas. In our institution, the method is exclusively used for the treatment of aggressive and recurrent facial tumours...
4.
Eriksson H, Nielsen K, Vassilaki I, Lapins J, Mikiver R, Lyth J, et al.
Cancers (Basel)
. 2021 Jul;
13(11).
PMID: 34200396
Background: The incidence of invasive cutaneous melanoma (CM) is increasing in Sweden. The aim was to present age- and sex-specific trends of the age-standardised incidence and the average annual percentage...
5.
Agnarsdottir M, Paaren H, Vassilaki I
Ups J Med Sci
. 2019 Oct;
124(4):260-264.
PMID: 31661366
Standardized care pathway (SCP) was introduced by the Swedish health authorities to eliminate unwanted delay in the diagnostics of cancer patients; for melanoma, SCP started in 2016. The aim of...
6.
Vassilaki I, Enache S, Lapins J
Lakartidningen
. 2017 May;
114.
PMID: 28485769
No abstract available.
7.
Eriksson H, Zebary A, Vassilaki I, Omholt K, Ghaderi M, Hansson J
JAMA Dermatol
. 2015 Jan;
151(4):410-6.
PMID: 25588152
Importance: BRAFV600E mutations are present in approximately 50% of cutaneous malignant melanomas (CMMs). The use of BRAFV600E mutation-specific monoclonal antibody VE1 immunohistochemical analysis may facilitate rapid detection of BRAFV600E mutations...
8.
Zebary A, Omholt K, Vassilaki I, Hoiom V, Linden D, Viberg L, et al.
J Dermatol Sci
. 2013 Sep;
72(3):284-9.
PMID: 23993026
Background: Acral lentiginous melanoma (ALM) accounts for <10% of all melanomas in Caucasians. Although the involvement of KIT, NRAS and BRAF mutations is well known in ALM, the impact of...
9.
Jahns A, Oprica C, Vassilaki I, Golovleva I, Palmer R, Alexeyev O
Anaerobe
. 2013 Jul;
23:48-54.
PMID: 23896347
Propionibacterium acnes (P. acnes) and Propionibacterium granulosum (P. granulosum) are common skin colonizers that are implicated as possible contributing factors in acne vulgaris development. We have established direct visualization tools...
10.
Zebary A, Omholt K, van Doorn R, Ghiorzo P, Harbst K, Hertzman Johansson C, et al.
J Invest Dermatol
. 2013 Jun;
134(1):287-290.
PMID: 23771122
No abstract available.